Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $3.2 million.

  • OptimizeRx's Cash from Operations rose 7878.28% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 85462.67%. This contributed to the annual value of $4.9 million for FY2024, which is 16752.76% up from last year.
  • As of Q3 2025, OptimizeRx's Cash from Operations stood at $3.2 million, which was up 7878.28% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Cash from Operations peaked at $4.6 million during Q2 2025, and registered a low of -$6.3 million during Q4 2023.
  • In the last 5 years, OptimizeRx's Cash from Operations had a median value of $1.5 million in 2023 and averaged $1.1 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 86883.63% in 2023, then skyrocketed by 256279.07% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Cash from Operations stood at -$1.3 million in 2021, then soared by 310.07% to $2.8 million in 2022, then tumbled by 323.22% to -$6.3 million in 2023, then surged by 103.16% to $198000.0 in 2024, then surged by 1517.17% to $3.2 million in 2025.
  • Its Cash from Operations stands at $3.2 million for Q3 2025, versus $4.6 million for Q2 2025 and $3.9 million for Q1 2025.